公开(公告)号：US12115211B2

公开(公告)日：2024-10-15

申请号：US17945054

申请日：2022-09-14

Applicant: Edgar Lee Hull, Jr.

Inventor： Edgar Lee Hull, Jr.

IPC: A61K38/44 ,  A61K31/122 ,  A61K31/197 ,  A61K31/198 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/714 ,  A61K33/00 ,  A61K33/04 ,  A61K33/30

CPC classification number: A61K38/443 ,  A61K31/122 ,  A61K31/197 ,  A61K31/198 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/714 ,  A61K33/00 ,  A61K33/04 ,  A61K33/30 ,  A61K38/446

Abstract: A vitamin for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

公开(公告)号：US20240325324A1

公开(公告)日：2024-10-03

申请号：US18738665

申请日：2024-06-10

Applicant: Diana Driscoll

Inventor： Diana Driscoll

IPC: A61K31/14 ,  A61K31/198 ,  A61K31/205 ,  A61K31/375 ,  A61K31/381 ,  A61K31/4748 ,  A61K31/51 ,  A61K33/06 ,  A61K36/9066 ,  A61P27/04 ,  G01N33/569

CPC classification number: A61K31/14 ,  A61K31/198 ,  A61K31/205 ,  A61K31/375 ,  A61K31/381 ,  A61K31/4748 ,  A61K31/51 ,  A61K33/06 ,  A61K36/9066 ,  A61P27/04 ,  G01N33/56972 ,  G01N2800/16 ,  G01N2800/52

Abstract: The present invention includes compositions and methods for the treatment or prevention of a disease or condition that causes dry eyes comprising: an effective amount of at least two active agents selected from: (1) at least one cholinesterase inhibitor; (2) at least one form of choline; (3) at least one form of carnitine; (4) at least one form of muscarinic agonist, sufficient to treat the disease or condition that causes dry eyes.

公开(公告)号：US20240319173A1

公开(公告)日：2024-09-26

申请号：US18613041

申请日：2024-03-21

Applicant: Wisconsin Alumni Research Foundation

Inventor： James Thomson ,  Jue Zhang

IPC: G01N33/50 ,  A61K31/137 ,  A61K31/202 ,  A61K31/365 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/47 ,  A61K31/51 ,  A61K31/519 ,  A61K31/55 ,  A61K31/56 ,  A61K31/63 ,  A61K31/685 ,  C12N5/071 ,  C12P3/00

CPC classification number: G01N33/5073 ,  A61K31/137 ,  A61K31/202 ,  A61K31/365 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/47 ,  A61K31/51 ,  A61K31/519 ,  A61K31/55 ,  A61K31/56 ,  A61K31/63 ,  A61K31/685 ,  C12N5/069 ,  C12P3/00 ,  C12N2506/45 ,  C12N2510/00

Abstract: The present disclosure provides reagents and methods for identifying compounds that promote arterial endothelial cell differentiation and nitric oxide production therefrom. Pharmaceutical compositions comprising compounds identified thereby are provided as are therapeutic methods using these pharmaceutical compositions for treating neural and cardiovascular diseases and disorders associated with deficient or disrupted nitric oxide production in arterial endothelial cells.

公开(公告)号：US12042505B2

公开(公告)日：2024-07-23

申请号：US17749887

申请日：2022-05-20

Applicant: Diana Driscoll

Inventor： Diana Driscoll

IPC: A61K31/685 ,  A61K31/14 ,  A61K31/205 ,  A61K31/4748 ,  A61K31/51 ,  A61K33/06 ,  A61P27/04

CPC classification number: A61K31/685 ,  A61K31/14 ,  A61K31/205 ,  A61K31/4748 ,  A61K31/51 ,  A61K33/06 ,  A61P27/04

Abstract: The present invention includes compositions and methods for the treatment or prevention of a disease or condition that causes dry eyes comprising: an effective amount of at least two active agents selected from: (1) at least one cholinesterase inhibitor; (2) at least one form of choline; (3) at least one form of carnitine; (4) at least one form of muscarinic agonist, sufficient to treat the disease or condition that causes dry eyes.

公开(公告)号：US20240197808A1

公开(公告)日：2024-06-20

申请号：US18510162

申请日：2023-11-15

Applicant: LIFTED BEVERAGES CORPORATION

Inventor： Reza Tirgari

IPC: A61K36/82 ,  A61K31/197 ,  A61K31/198 ,  A61K31/375 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/52 ,  A61K31/7004 ,  A61K31/714 ,  A61K33/30 ,  A61K36/258 ,  A61K36/9066

CPC classification number: A61K36/82 ,  A61K31/197 ,  A61K31/198 ,  A61K31/375 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/52 ,  A61K31/7004 ,  A61K31/714 ,  A61K33/30 ,  A61K36/258 ,  A61K36/9066

Abstract: Compositions and methods for mitigating and preventing the effects of alcohol consumption are provided. A first composition can be ingested by an individual prior to or within six hours of alcohol consumption. A second composition can be ingested by the individual either at the onset of negative symptoms associated with alcohol consumption or the morning following alcohol consumption. The first and second compositions can be ingested individually, or in combination. When both the first and second composition are consumed, the first composition is to be consumed prior to the second composition, and both are to be consumed in a timely manner. Both compositions can be administered orally. The compositions can each be administered as a fluid solution. Only one serving of each composition is required to achieve the desired effects. Results are strengthened when both compositions are consumed in combination.

公开(公告)号：US20240197751A1

公开(公告)日：2024-06-20

申请号：US18586055

申请日：2024-02-23

Applicant: Usso Barnas ,  Arian Jankur Can Barnas

Inventor： Usso Barnas

IPC: A61K31/5513 ,  A61K31/135 ,  A61K31/167 ,  A61K31/196 ,  A61K31/4415 ,  A61K31/51 ,  A61K31/525 ,  A61K31/573 ,  A61K31/714

CPC classification number: A61K31/5513 ,  A61K31/135 ,  A61K31/167 ,  A61K31/196 ,  A61K31/4415 ,  A61K31/51 ,  A61K31/525 ,  A61K31/573 ,  A61K31/714

Abstract: The present invention discloses a pharmaceutical composition, wherein the pharmaceutical composition is an injectable or infusable pharmaceutical composition, the pharmaceutical composition comprising:



a) a pharmaceutically acceptable solvent,
b) a first compound comprising diclofenac or a pharmaceutically acceptable salt or solvate thereof,
c) a second compound comprising metamizole or tramadol or a pharmaceutically acceptable salt or solvate thereof, and
d) a third compound selected as at least one benzodiazepine or a pharmaceutically acceptable salt or solvate thereof,

the pharmaceutical composition further comprising a cortisone derivative or a pharmaceutically acceptable salt or solvate thereof.

公开(公告)号：US20240189369A1

公开(公告)日：2024-06-13

申请号：US18589539

申请日：2024-02-28

Applicant: Concerto Biosciences, Inc.

Inventor： Jared KEHE ,  Bernardo CERVANTES ,  Cheri ACKERMAN ,  Abdulrahman HASSABALLAH ,  Keaton ARMENTROUT

IPC: A61K35/741 ,  A61K31/51 ,  A61P31/04 ,  C12N1/20 ,  C12R1/07

CPC classification number: A61K35/741 ,  A61K31/51 ,  A61P31/04 ,  C12N1/20 ,  C12R2001/07

Abstract: Provided herein are compositions, methods, kits, and devices for the treatment of skin diseases. Also provided herein are isolated and purified bacteria, excipients, carriers, dosage forms and routes of administration for such bacteria. Furthermore, provided herein are isolated and purified mixtures of bacteria, excipients, carriers, dosage forms and routes of administration for such mixtures. Also provided herein are conditions for treatment with bacteria and bacterial mixtures.

公开(公告)号：US11951144B2

公开(公告)日：2024-04-09

申请号：US17268316

申请日：2018-09-12

Applicant: PM-INTERNATIONAL AG

Inventor： Rolf Sorg ,  Tobias Kühne ,  Christian Lauinger ,  Wilhelm Messer

IPC: A61K36/00 ,  A23L33/105 ,  A23L33/125 ,  A23L33/135 ,  A23L33/14 ,  A23L33/15 ,  A23L33/16 ,  A23L33/22 ,  A61K31/12 ,  A61K31/197 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/522 ,  A61K31/525 ,  A61K31/593 ,  A61K31/714 ,  A61K33/06 ,  A61K33/30 ,  A61K33/34 ,  A61K35/20 ,  A61K36/064 ,  A61K36/67 ,  A61K36/9068 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/46 ,  A61K47/69

CPC classification number: A61K36/67 ,  A23L33/105 ,  A23L33/125 ,  A23L33/135 ,  A23L33/14 ,  A23L33/15 ,  A23L33/16 ,  A23L33/22 ,  A61K31/12 ,  A61K31/197 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/522 ,  A61K31/525 ,  A61K31/593 ,  A61K31/714 ,  A61K33/06 ,  A61K33/30 ,  A61K33/34 ,  A61K35/20 ,  A61K36/064 ,  A61K36/9068 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/46 ,  A61K47/6951 ,  A23V2002/00 ,  A23V2400/113 ,  A23V2400/173

Abstract: A composition, containing



a pepper component,
a curcumin-cyclodextrin mixture and
a mixture of fruits, vegetables and spices.

公开(公告)号：US11938100B2

公开(公告)日：2024-03-26

申请号：US17385611

申请日：2021-07-26

Applicant: Kedar Prasad

Inventor： Kedar Prasad

IPC: A61K31/07 ,  A23L33/105 ,  A23L33/155 ,  A23L33/16 ,  A61K31/015 ,  A61K31/05 ,  A61K31/12 ,  A61K31/122 ,  A61K31/197 ,  A61K31/198 ,  A61K31/352 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/714 ,  A61K33/04 ,  A61K33/06 ,  A61K33/24 ,  A61K33/30

CPC classification number: A61K31/07 ,  A23L33/105 ,  A23L33/155 ,  A23L33/16 ,  A61K31/015 ,  A61K31/05 ,  A61K31/12 ,  A61K31/122 ,  A61K31/197 ,  A61K31/198 ,  A61K31/352 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/714 ,  A61K33/04 ,  A61K33/06 ,  A61K33/24 ,  A61K33/30 ,  A23V2002/00

Abstract: A formulation comprising at least on vitamin, at least one antioxidant, at least one mineral, at least one plant based nutrient and sodium.

公开(公告)号：US20240009226A1

公开(公告)日：2024-01-11

申请号：US18471634

申请日：2023-09-21

Applicant: NVIDIA Corporation

Inventor： Gregory MUTHLER ,  John BURGESS

IPC: A61K31/714 ,  A61K31/4415 ,  A61K31/198 ,  A61K31/197 ,  A61K31/14 ,  A61K31/385 ,  A61K31/205 ,  A61K31/51 ,  A61K31/4188 ,  A61K31/519 ,  A61K31/525 ,  A61K31/19

CPC classification number: A61K31/714 ,  A61K31/4415 ,  A61K31/198 ,  A61K31/197 ,  A61K31/14 ,  A61K31/385 ,  A61K31/205 ,  A61K31/51 ,  A61K31/4188 ,  A61K31/519 ,  A61K31/525 ,  A61K31/19

Abstract: Ray tracing hardware accelerators supporting multiple specifiers for controlling the traversal of a ray tracing acceleration data structure are disclosed. For example, traversal efficiency and complex ray tracing effects can be achieved by specifying traversals through such data structures using both programmable ray operations and explicit node masking. The explicit node masking utilizes dedicated fields in the ray and in nodes of the acceleration data structure to control traversals. Ray operations, however, are programmable per ray using opcodes and additional parameters to control traversals. Traversal efficiency is improved by enabling more aggressive culling of parts of the data structure based on the combination of explicit node masking and programmable ray operations. More complex ray tracing effects are enabled by providing for dynamic selection of nodes based on individual ray characteristics.